Everence Capital Management Inc. Sells 1,340 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Everence Capital Management Inc. decreased its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 44.1% during the 3rd quarter, HoldingsChannel reports. The firm owned 1,700 shares of the company’s stock after selling 1,340 shares during the quarter. Everence Capital Management Inc.’s holdings in IDEXX Laboratories were worth $859,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of IDXX. Riverview Trust Co bought a new stake in shares of IDEXX Laboratories in the 1st quarter valued at about $26,000. Crewe Advisors LLC bought a new stake in shares of IDEXX Laboratories in the 1st quarter valued at about $26,000. Ridgewood Investments LLC bought a new stake in shares of IDEXX Laboratories in the 2nd quarter valued at about $27,000. Institutional & Family Asset Management LLC bought a new stake in shares of IDEXX Laboratories in the 2nd quarter valued at about $28,000. Finally, Strategic Investment Solutions Inc. IL bought a new stake in shares of IDEXX Laboratories in the 2nd quarter valued at about $36,000. Institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Stock Down 0.8 %

IDXX stock traded down $3.77 during trading on Monday, reaching $453.97. 568,298 shares of the stock were exchanged, compared to its average volume of 472,918. The firm’s 50 day moving average is $487.50 and its 200 day moving average is $491.33. IDEXX Laboratories, Inc. has a twelve month low of $372.50 and a twelve month high of $583.39. The company has a current ratio of 1.37, a quick ratio of 1.03 and a debt-to-equity ratio of 0.33. The firm has a market cap of $37.49 billion, a P/E ratio of 44.03, a price-to-earnings-growth ratio of 4.14 and a beta of 1.33.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings results on Tuesday, August 6th. The company reported $2.44 earnings per share for the quarter, missing analysts’ consensus estimates of $2.88 by ($0.44). IDEXX Laboratories had a return on equity of 57.03% and a net margin of 22.34%. The firm had revenue of $1 billion for the quarter, compared to analyst estimates of $1.01 billion. During the same period last year, the company posted $2.67 earnings per share. The firm’s quarterly revenue was up 6.4% compared to the same quarter last year. As a group, research analysts forecast that IDEXX Laboratories, Inc. will post 10.44 EPS for the current year.

Analysts Set New Price Targets

IDXX has been the topic of a number of analyst reports. Piper Sandler reduced their price target on IDEXX Laboratories from $600.00 to $520.00 and set a “neutral” rating on the stock in a research report on Wednesday, August 14th. Stifel Nicolaus reduced their price target on IDEXX Laboratories from $510.00 to $500.00 and set a “hold” rating on the stock in a research report on Thursday, October 10th. JPMorgan Chase & Co. dropped their price objective on IDEXX Laboratories from $630.00 to $575.00 and set an “overweight” rating on the stock in a research note on Friday, October 11th. BTIG Research began coverage on IDEXX Laboratories in a research note on Thursday, July 25th. They issued a “buy” rating and a $580.00 price objective on the stock. Finally, StockNews.com downgraded IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Wednesday, July 10th. Three research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $574.13.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.